New York, New York 10016

  • Unspecified Adult Solid Tumor, Protocol Specific


Phase I trial to study the effectiveness of paclitaxel plus topotecan in treating patients who have solid tumors. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.

Study summary:

OBJECTIVES: I. Determine the maximum tolerated dose and quantitative and qualitative toxic effects of topotecan and paclitaxel in patients with solid tumors. II. Determine the antitumor activity of this regimen in these patients. OUTLINE: This is a dose escalation study of topotecan and paclitaxel. Patients receive paclitaxel IV over 3 hours on day 1 followed 2-6 hours later by topotecan IV continuously on days 1-14. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of topotecan and paclitaxel until the maximum tolerated dose (MTD) of each drug is determined. The MTD is defined as the highest dose preceding that at which 2 of 6 patients experience dose-limiting toxicity. PROJECTED ACCRUAL: Approximately 10-20 patients will be accrued for this study within 8-12 months.


DISEASE CHARACTERISTICS: - Histologically proven solid tumor - Measurable or evaluable disease - Measurable disease defined as tumor outside prior radiotherapy fields and reproducibly measurable in 2 dimensions on physical exam, x-ray, CT, or MRI PATIENT CHARACTERISTICS: - Age: 18 and over - Performance status: 0 or 1 - Life expectancy: At least 12 weeks - WBC at least 4,000/mm3 - Platelet count at least 100,000/mm3 - Bilirubin no greater than 1.5 mg/dL - AST less than 3 times normal - Alkaline phosphatase less than 3 times normal - Creatinine no greater than 1.5 mg/dL - No poorly controlled angina - No history of congestive heart failure - No myocardial infarction within the past 6 months - Not pregnant or nursing PRIOR CONCURRENT THERAPY: - No concurrent prophylactic hematopoietic growth factors - No concurrent medications altering cardiac conduction



Primary Contact:

Study Chair
Howard S. Hochster, MD
New York University School of Medicine

Backup Contact:


Location Contact:

New York, New York 10016
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source:

Date Processed: March 26, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on The form below is not enabled.